Key Findings
Clarivate released its updated list of ‘Drugs to Watch’ for mid-2026. This report clearly indicates that AI drug discovery and innovative drug delivery system (DDS) technologies are the primary trends driving the future pharmaceutical market. The selected drugs on the list are assessed as having the potential to address unmet medical needs across various disease areas and possess the potential to become blockbusters, generating over $1 billion in annual sales in the future.
Technical / Clinical Details
The ‘Drugs to Watch in 2026’ list primarily includes the following types of drugs in late-stage clinical trials: 1) **AI-Designed Drugs**: Multiple newly designed small molecules and biopharmaceutical candidates, specifically targeting cancer, neurodegenerative diseases, and rare diseases, have been selected. These drugs are expected to demonstrate high selectivity and efficacy against targets that were challenging to address with conventional drug discovery processes. 2) **Drugs with Innovative DDS**: DDS technologies incorporating lipid nanoparticles (LNPs) and targeted carriers, which enable efficient delivery of RNAi therapeutics and gene therapies, are gaining attention. For instance, an LNP-siRNA formulation targeting specific liver diseases has shown over 70% suppression of disease-related protein expression on average in Phase 3 trials, along with a favorable safety profile. 3) **Targeted Protein Degraders (TPDs)**: As a novel modality in cancer treatment, drugs that degrade ‘undruggable’ target proteins, which were challenging for conventional inhibitors, have been selected. These drugs hold the potential for sustained pharmacological effects and overcoming drug resistance. Clarivate’s assessment comprehensively evaluates the favorable clinical data demonstrated by these drugs and their strong market positioning.
Background & Context
The pharmaceutical industry is undergoing a major transformation, driven by accelerating technological innovation and a shift towards patient-centric healthcare. AI holds the potential to streamline the entire drug discovery process and identify previously overlooked therapeutic opportunities. Meanwhile, DDS technologies enhance drug stability, target specificity, and intracellular delivery efficiency, thereby maximizing the therapeutic effects of existing drugs and enabling the practical application of novel modalities (e.g., gene therapy, RNA therapy). Clarivate’s ‘Drugs to Watch’ report serves as a crucial resource for pharmaceutical strategists, investors, and healthcare professionals to understand future market trends and growth drivers.
Strategic Significance & Outlook
Clarivate’s report suggests that AI drug discovery and DDS technologies are highly likely to fundamentally transform the pharmaceutical industry landscape in the coming years. As these technologies mature and more innovative drugs enter the market, treatment options for intractable diseases are expected to expand, improving patient prognosis and quality of life. Furthermore, the convergence of AI and DDS will drive the further advancement of personalized medicine, leading to the delivery of optimized therapies for individual patients. Pharmaceutical companies are urged to accelerate investment in these advanced technologies and form strategic partnerships to establish future competitive advantages.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments